Evidence map›Paper›PMID 34953958›Full record

ArticleJournal of hepatology2022

Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex.

Amaia Navarro-Corcuera, Tejasav S Sehrawat, Nidhi Jalan-Sakrikar, Hunter R Gibbons, Nicholas E Pirius, Shalil Khanal, Feda H Hamdan, Sayed Obaidullah Aseem, Sheng Cao, Jesus M Banales and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. LncRNA-encoded peptides in cancer.Journal of hematology & oncology · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Amaia Navarro-CorcueraDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Tejasav S SehrawatDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Nidhi Jalan-SakrikarDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Hunter R GibbonsDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Nicholas E PiriusDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States.
Shalil KhanalDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Feda H HamdanDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Sayed Obaidullah AseemDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Sheng CaoDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Jesus M BanalesDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, CIBERehd, Ikerbasque, San Sebastian, Spain.
Ningling KangThe Hormel Institute, University of Minnesota, Austin, MN, United States.
William A FaubionDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Nicholas F LaRussoDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States.
Vijay H ShahDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States.
Robert C HuebertDivision of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, United States; Gastroenterology Research Unit; Mayo Clinic and Foundation, Rochester, MN, United States. Electronic address: huebert.robert@mayo.edu.
Mayo Clinic · USIkerbasque · ESUniversity of Minnesota · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
The Pathobiology of Hepatic EpitheliaR01DK024031 · NIDDK · MAYO CLINIC ROCHESTER · PI LARUSSO, NICHOLAS F. · 1986 to 2023
$10.4M
Pathophysiology of Biliary DiseaseR01DK057993 · NIDDK · MAYO CLINIC ROCHESTER · PI LARUSSO, NICHOLAS F., O'HARA, STEVEN P · 2001 to 2025
$7.1M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
HEPATIC STELLATE CELL REGULATION OF METASTATIC GROWTH IN THE LIVERR01CA160069 · NCI · UNIVERSITY OF MINNESOTA · PI NINGLING KANG · 2011 to 2026
$5.2M
Molecular Mechanisms of Cholestatic FibrogenesisR01DK117861 · NIDDK · MAYO CLINIC ROCHESTER · PI Robert Christian Huebert · 2019 to 2026
$2.8M
Molecular Mechanisms of Portal HypertensionR56DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H · 2007 to 2007
$378k
Epigenetic Regulation in Primary Sclerosing CholangitisR03DK113339 · NIDDK · MAYO CLINIC ROCHESTER · PI HUEBERT, ROBERT CHRISTIAN · 2018 to 2019
$159k
NCI NIH HHS R01 CA160069NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK024031NIDDK NIH HHS R01 DK057993NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R01 DK117861NIDDK NIH HHS R03 DK113339NIDDK NIH HHS R56 DK059615
6 · The paper itself

Abstract

BACKGROUND &

aimsBiliary disease is associated with a proliferative/fibrogenic ductular reaction (DR). p300 is an epigenetic regulator that acetylates lysine 27 on histone 3 (H3K27ac) and is activated during fibrosis. Long non-coding RNAs (lncRNAs) are aberrantly expressed in cholangiopathies, but little is known about how they recruit epigenetic complexes and regulate DR. We investigated epigenetic complexes, including transcription factors (TFs) and lncRNAs, contributing to p300-mediated transcription during fibrosis.

methodsWe evaluated p300 in vivo using tamoxifen-inducible, cholangiocyte-selective, p300 knockout (KO) coupled with bile duct ligation (BDL) and Mdr KO mice treated with SGC-CBP30. Primary cholangiocytes and liver tissue were analyzed for expression of Acta2-as1 lncRNA by qPCR and RNA in situ hybridization. In vitro, we performed RNA-sequencing in human cholangiocytes with a p300 inhibitor. Cholangiocytes were exposed to lipopolysaccharide (LPS) as an injury model. We confirmed formation of a p300/ELK1 complex by immunoprecipitation (IP). RNA IP was used to examine interactions between ACTA2-AS1 and p300. Chromatin IP assays were used to evaluate p300/ELK1 occupancy and p300-mediated H3K27ac. Organoids were generated from ACTA2-AS1-depleted cholangiocytes.

resultsBDL-induced DR and fibrosis were reduced in Krt19-Cre

conclusionCholangiocyte-selective p300 KO or p300 inhibition attenuate DR/fibrosis in mice. ACTA2-AS1 influences recruitment of p300/ELK1 to specific promoters to drive H3K27ac and epigenetic activation of proliferative/fibrogenic genes. This suggests that cooperation between epigenetic co-activators and lncRNAs facilitates DR/fibrosis in biliary diseases. LAY SUMMARY: We identified a three-part complex containing an RNA molecule, a transcription factor, and an epigenetic enzyme. The complex is active in injured bile duct cells and contributes to activation of genes involved in proliferation and fibrosis.

Indexed as

RNA, Long NoncodingAnimalsBile DuctsCell ProliferationFibrosisLipopolysaccharidesLiverMiceMice, KnockoutLipopolysaccharidesRNA, Long NoncodingACTA2-AS1cholangiocyteductular reactionELK1p300

Identifiers

PMID34953958
PMCPMC8934273
OpenAlexW4200248474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.